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Spiroindolone NITD609 is a novel antimalarial that 
targets the P-type ATPase PfATP4  
Helen Turner
Department of Life, Health and Chemical Sciences, The Open 
University, Walton Hall, Milton Keynes, MK7 6AA, UK. 
Abstract: 
Malaria is caused by the Plasmodium parasite and is a major health problem leading to many 
deaths worldwide.  Lack of a vaccine and increasing drug resistance highlights the need for 
new antimalarial drugs with novel targets.    Antiplasmodial activity of spiroindolones was 
discovered through whole-cell, phenotypic screening methods.  Optimisation of the lead 
spiroindolone improved both potency and pharmacokinetic properties leading to drug 
candidate NITD609 which has produced encouraging results in clinical trials.  Spiroindolones 
inhibit PfATP4, a P-type Na+-ATPase in the plasma membrane of the parasite, causing a fatal 
disruption of its sodium homeostasis.  Other diverse compounds from the Malaria Box appear 
to target PfATP4 warranting further research into its structure and binding with NITD609 and 
other potential antimalarial drugs. 
Key Terms 
 Apicomplexan organisms: a group of parasitic eukaryotic microorganisms that includes
Plasmodium and Toxoplasma.
 Malaria box: an open access collection of 400 structurally diverse antimalarial
compounds selected from whole-cell drug screen hits.  It consists of 200 drug-like
compounds and 200 probe-like compounds, all with unknown mechanism of action.
 NGBS Consortium: public-private collaboration involved in a malaria drug discovery
programme to identify new chemotypes for the development of malaria treatments.
 P-type adenosine triphosphatase (P-type ATPase): a family of evolutionary related
membrane-bound pumps that self-phosphorylate at a conserved aspartate residue.
Most P-type ATPases pump cations enabling the maintenance of electrochemical
gradients across cell membranes.
 Plasmodium bergei: a murine malaria widely used in an animal model for malaria
research.
 Spiroindolones (Spirotetrahydro beta-carbolines): synthetic compound with two
stereocentres consisting of a beta-carboline structure connected through a central
spiroatom to an indole structure.
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Introduction / background 
Malaria is an infectious disease caused by the malaria parasite Plasmodium and transmitted 
by female Anopheles mosquitoes.  The four main species that infect humans are Plasmodium 
falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malariae.  P. falciparum 
and P. vivax are the most common with P. falciparum causing the most deaths globally [1].  
The World Health Organisation estimates there were 207 million cases of malaria and 627,000 
malaria deaths in 2012 [2] which is a great improvement since 20 years previous when it 
caused over 1 million deaths per year [3].   
 
 
Figure 1.  Malaria parasite life cycle.  The life cycle is complex involving both human and 
mosquito hosts. Figure copied from [4] 
 
The life cycle of the malaria parasite is complex with several life stages involving both 
mosquito and human hosts (Figure 1). When the female Anopheles mosquito bites sporozoites 
are injected with the saliva into the human host (Step 1).  The sporozoites travel to the liver 
and infect the hepatocytes (Step 2) where they develop and multiply asexually to form exo-
erythrocytic schizonts (Step 3).  These schizonts rupture releasing merozoites (Step 4) into 
the bloodstream where they enter the erythrocytes (Step 5).  They replicate synchronously in 
the erythrocytes causing the clinically manifested cycle of fever.  Ring-stage trophozoites 
mature into schizonts which rupture releasing merozoites (Step 6).  Some of the merozoites 
develop into male and female gametocytes (Step 7) which are ingested with the blood into the 
female mosquito gut (Step 8).  The male and female gametes fuse to form zygotes (Step 9) in 
the mosquito’s stomach.  They then elongate and become motile ookinetes (Step 10) which 
migrate from the gut and form oocysts (Step 11).  The oocysts undergo meiotic division to 
form sporozoites (Step 12) which migrate to the salivary gland of the mosquito ready to be 
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injected into the next human host (Step 1).  In P. vivax and P. ovale some of the liver-stage 
parasites can remain dormant as hypnozoites for weeks or years.  Reactivation of the 
hypnozoites causes relapses in the disease. 
Currently there is no vaccine licensed for use against malaria however it is hoped a vaccination 
that offers some protection will be introduced in 2015. The RTS,S vaccine is undergoing phase 
3 trials and initial results showed it reduced the incidence of malaria by half in children of 12-
17 months old for 12 months after vaccination [5].  Most existing antimalarial drugs act against 
the asexual blood stages of the parasite.  Primaquine is the only drug approved that acts 
against the dormant liver stages of P. vivax whose reactivation lead to relapse [6].  For many 
years chloroquine and sulphadoxine-pyrimethamine were the principal antimalarial treatments 
however resistance to both drugs led to increased morbidity and mortality from malaria. 
Artemisinin-based combination therapies (ACTs) , which contain a combination of an 
artemisinin derivative and another antimalarial drug with a different mechanism of action, are 
recommended to reduce the risk of drug resistance [1].   ACTs are a major factor in the 
increased malaria control, consequently it is of great concern that P. falciparum has developed 
some resistance to artemisinin derivatives in South East Asia [7].   
Increasing resistance of Plasmodium to the existing malaria treatments including artemisinin 
and its derivatives [7] highlight the need for new antimalarial drug therapies.  Key factors in 
considering the target product profile (TPP) include the vulnerability of many of the patients 
(many of whom are young children and pregnant women), the lack of medical supervision 
under which drugs are administered and the need for patient compliance. 
Ideally new antimalarial drugs should [1,8]: 
 be effective against the blood stages of the key species of parasite that cause malaria 
in humans, including those with drug-resistance, 
 kill the hypnozoites of P. vivax  and P. ovale therefore preventing relapse, 
 kill the gametocytes to prevent transmission, 
 kill sporozoites and exo-erythrocytic schizonts therefore preventing the initial infection 
when used prophylactically, 
 have a novel mechanism of action, 
 have good oral availability, 
 be safe, 
 cure by a single dose, 
 be cheap to produce. 
 
 
Discovery of spiroindolones as antimalarial agents 
At a time when there was optimism that the ration drug design approach, based on the 
molecular understanding of the biology of the malaria parasite, would produce new 
antimalarial drugs the spiroindolones were identified using older, whole-cell, phenotypic 
screening methods based on the growth inhibition of P. falciparum [9].  A library of 12,000 
pure natural and structurally similar synthetic molecules was screened using whole-cell 
proliferation assays with cultured cells from intra-erythrocytic Plasmodium parasites [10,11] 
(Figure 2).  From the 275 compounds that had submicromolar activity against P. falciparum 
those that weren’t active against multi-drug resistant forms of the parasite and those that were 
cytotoxic to mammalian cells were excluded leaving 17 compounds.  Since it is important that 
a new antimalarial drug can be administered in tablet form the oral bioavailability of the 
remaining compounds was assessed.  Based on its activity against Plasmodium and 
favourable pharmacokinetic profile a synthetic compound (1) related to the spiroazepineindole 
4 
 
class was selected for medicinal chemistry lead optimisation. Compound 1  had good oral 
bioavailability in mice with F = 59% and an oral half-life of nearly 4 hours [6]. 
 
 
Figure 2. Overview of the screening process that identified the spiroindolone lead 
compound.  Figure copied from [12]. 
 
The initial compound identified (1) was a racemic mixture consisting of 1R,3S & 1S,3R and 
1S,3S & 1R,3R pairs of enantiomers that had moderate potency against wild-type (NF54) and 
chloroquine-resistant (K1) strains of Plasmodium (Figure 3).  A single 100mg/kg dose of 
racemic compound 1 led to a 96% decrease in parasitaemia in the P. berghei-infected mouse 
model. 
The reaction to create compound 1 yielded an unequal mixture such that there was a 9:1 
excess of the 1R,3S & 1S,3R pair of enantiomers [11].  Structure-activity relationship (SAR) 
analysis showed that the 1R,3S stereoisomer (1a) was over 250 times more potent against P. 
falciparum than the 1S,3R stereoisomer (1b) (Figure 3).  SAR analysis of further spiroindolone 
compounds consistently indicated that the 1R,3S stereoisomer was essential to be active 
against P. falciparum [11].  Only one enantiomer being active suggests the existence of a 
discreet target.   
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Compound 1 – racemic 
NF54 EC50 = 90 nM 
K1 EC50 = 80nM  
1R
3S
 
Compound 1a – 1R,3S active 
enantiomer 
NF54 EC50 = 20 nM 
K1 EC50 = 30 nM 
1S
3R
 
Compound 1b – 1S,3R inactive 
enantiomer 
NF54 EC50 = >5000 nM 
K1 EC50 = > 5000 nM 
Figure 3. Molecular structure of the lead compound.  The racemic 1, active enantiomer 1a 
(1R,3S) and inactive enantiomer 1b (1S,3R).  Data from [11]. 
 
 
Optimisation of spiroindolone lead led to drug candidate NITD609 
Most antimalarial drugs act on the parasite in the blood stages therefore it is desirable for the 
drug to stay in the plasma compartment and not to enter the body fat.  Substitutions to the 
bromine atom were made to make the molecule less lipophilic since lipophilic molecules are 
more likely to enter the adipose tissue from the plasma.   Replacing the 5’-bromide with a 5’-
chloro produced a compound with improved balance of potency, pharmacokinetics and 
synthetic accessibility [11] (Figure 4 – Compound 2).  Mono- and di-substitutions with other 
halogens produced unfavourable results. 
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Compound 2 (racemate) – 5’-bromo 
replaced with 5’-chloro 
NF54 EC50 = 84 nM 
 
Compound 3 (racemate) 
NF54 EC50 = 86 nM 
 
Compound 4 (racemate) 
NF54 EC50 = 27 nM 
K1 EC5 = 21 nM 
 
Compound 4a (1R,3S) 
NF54 EC50 = 9.2 nM 
 
Compound 5 (racemate) 
NF54 EC50 = 126 nM 
K1 EC5 = 104 nM 
Figure 4. Compounds 2, 3, 4, 4a & 4.  5’-bromo replaced with 5-‘chloro (2).  Alterations to the 
azepine ring to give compound 4.  Removal of the methyl from the 7-membered ring does 
affect potency (2 & 3) however decreases potency 5-fold when removed from the 6-membered 
ring (4 & 5). 
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There was some scope for alterations to the central seven-membered azepine ring [6] (Figure 
4).  Adding another carbon atom to the azepine ring of compound 2 (NF54 IC50 = 84nM) 
produced an inactive compound (structure not shown: NF54 IC50 > 5000nM) however potency 
was increased 3-fold when removing a carbon atom to make a 6-membered ring tetrahydro-
β-carboline derivative (4) (Figure 4).  Removal of the C3 methyl from the tetra-hydro-β-
carboline structure resulted in nearly a 5-fold loss of potency (5) however its removal did not 
affect the potency for the azepineindole structure (3).  The C3 methyl could only be substituted 
with trifluoromethyl. 
 
 
Compound 4  
(racemate) 
4a 
(1R,3S) 
4b 
(1S,3R) 
NF54 IC50 (nM) 27 9.2 >5000 
In vitro (liver microsomes) 
Clearance CLint 
   
Mouse Medium High Low 
Human Medium High Low 
In vitro (liver microsomes) 
Microsomal Half-life t1/2 (min) 
   
Mouse 26.5 1.8 103 
Human 9.9 1.2 95 
CYP2C9 inhibition (μM) n/a 1.51 >10.00 
In vivo (mice) 
Clearance CL (mL/min/kg) 
n/a 49.66 n/a 
Table 1. Pharmacokinetic profile of spiroindolone 4.  In vitro metabolic stability measured 
using liver microsomes.  In vivo clearance measured in mice at a single 5mg/kg iv dose.  CL 
= clearance; CLint = Intrinsic clearance; n/a = not available. Data from [6,11] 
 
The spiroindolones represented good drug candidates as they generally had good in vitro 
solubility and permeability, were not cytotoxic to human cell lines, had low cardiotoxicity 
potential, low genotoxicity  and did not significantly bind to human receptors, kinases or ion 
channels [11].  There was a significant difference in the metabolic stability and CYP450 
inhibition between the pairs of enantiomers with the inactive 1S,3R having more favourable 
properties [11].  A microsomal clearance assay was used to predict the metabolic stability and 
it was found that the active 1R,3S enantiomers had a high clearance, poor metabolic stability 
with liver microsomes and inhibited CYP2C9 preferentially (Table 1).   
The benzene ring of the indole moiety was identified as being susceptible to metabolism by 
oxidation and therefore leading to high clearance.  A systematic approach was taken to 
modifying the indole ring of compound 4a to improve its half-life in the presence of liver 
microsomes (Figure 5).  Aryl halides are usually too stable to be metabolised so halides were 
added to the benzene ring to protect it from oxidation.  Substituting a fluorine atom at C7 
position of the indoline was the most effective in increasing the half-life (7a) [6].  Substitutions 
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on C5, C6 and C8 did not improve the metabolic stability however they did increase the 
potency with substitutions at C6 and C7 being the most effective (9a & 10a).    
 
Compound 4a (1R,3S) 
NF54 EC50 = 9 nM 
Hepatic CLint mouse = high 
Hepatic CLint human = high 
CYP2C9 inhibition (μM) = 1.51 
In vivo CL (mL/min/kg) = 49.66 
 
Compound 6a (1R,3S) 
NF54 EC50 = 3 nM 
Hepatic CLint mouse = high 
Hepatic CLint human = medium 
Half-life t1/2 mouse (min) = 4.2 
Half-life t1/2 human (min) = 10 
CYP2C9 inhibition (μM) = 1.72 
In vivo CL (mL/min/kg) = 24.01 
 
Compound 7a (1R,3S) 
NF54 EC50 = 3.5 nM 
Hepatic CLint mouse = low 
Hepatic CLint human = low 
Half-life t1/2 mouse (min) = 53 
Half-life t1/2 human (min) = 53 
 
 
Compound 8a (1R,3S) 
NF54 EC50 = 4 nM 
Hepatic CLint mouse = low 
Hepatic CLint human = low 
CYP2C9 inhibition (μM) = 4.11 
In vivo CL (mL/min/kg) = 60.08 
 
Compound 9a (1R,3S) (NITD609) 
NF54 EC50 = 0.9 nM 
Hepatic CLint mouse = low 
Hepatic CLint human = low 
Half-life t1/2 mouse (min) = 49 
Half-life t1/2 human (min) = 76 
CYP2C9 inhibition (μM) = 5.42 
In vivo CL (mL/min/kg) = 9.75 
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Compound 10a (1R,3S) 
NF54 EC50 = 0.2 nM 
Hepatic CLint mouse = low 
Hepatic CLint human = low 
Half-life t1/2 mouse (min) = 49 
Half-life t1/2 human (min) = 56 
CYP2C9 inhibition (μM) = 7.35 
In vivo CL (mL/min/kg) = 8.53 
Figure 5. Substitutions on the indole ring system improved the metabolic stability and 
potency of the spiroindolones. Data from [6,11]. 
 
 
 
potential Van der Waals
Protects from metabolism
Increased potency
Required on 6-membered
 but not 7-membered ring
potential hydrogen bond 
acceptor / donor
 
 
Figure 6.  Top: spiroindolone pharmacophore; Middle: molecular structure of NITD609 
showing key features; Bottom 3-dimensional structure of NITD609.  R1 = CH3 or CF3; R2 
= Cl or Fl; R3 = H, F or CL; R4 = H, F or Cl. 
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The spiroindolones had been identified as potential new antimalarial drugs however their 
mechanism of action was unknown.  Compound 9a (NITD609, Figure 6) showed the best 
combination of potency and oral exposure and went forward for further preclinical evaluation. 
 
 
NITD609 displays antimalarial activity against the asexual blood stage, gametocyte and 
oocyte stages of Plasmodium. 
The optimisations from in vitro studies using microsomal clearance assays proved to 
correspond well to antimalarial activity in the P. berghei-infected mouse model with 4a, 9a & 
10a demonstrating better efficacy in reducing parasitaemia than chloroquine and artesunate 
[6].  Each of the spiroindolones prolonged survival of the mice more than chloroquine and 
artesunate when a single oral dose of 30mg/kg was administered (Table 2).  Even better 
results were achieved when dosed orally once daily for 3 days with 60-90% of mice being 
cured.  
 
Compound 
1 x 30 mg/kg 3 x 30 mg/kg 
Activity 
(%) 
Survival 
(days) 
Cure rate 
(%) 
Activity 
(%) 
Survival 
(days) 
Cure rate 
(%) 
Chloroquine 99.7 8.7 0 99.9 14.0 0 
Artesunate 92.2 7.3 0 99.0 11.8 0 
4a 99.9 10.7 0 99.9 18.8 60 
9a 
(NITD609) 
99.6 13.3 0 99.8 29.1 90 
10a 99.6 12.0 0 99.8 23.8 80 
Table 2.  In vivo antimalarial activity in P. berghei-infected mouse model.  Data from [6]. 
 
NITD609 achieved in vitro inhibitory concentration (IC50) values of 0.5 to 1.4nM against a panel 
of wild-type and drug-resistant P. falciparum with no significant decrease in activity against 
the drug-resistant strains [10].  Resistant strains included those with resistance against 
chloroquine, pyrimethamine, and mefloquine however artemisinin-resistant strains were not 
included in the panel. 
Ex vivo assays were performed using fresh isolates of P. falciparum and P. vivax from malaria 
patients on the Thai-Burmese border where chloroquine resistance is known to occur [10].  
NITD609 and artesunate were equally effective with IC50 <10nM against both P. falciparum 
and P. vivax.  The asexual blood stages are associated with the morbidity and mortality of 
malaria.  In vitro sensitivity assays using P. falciparum at ring, trophozoite and schizont phases 
of the human blood stages determined that NITD609 was most effective against schizonts 
[10]. 
As well as being effective against the asexual blood stages, another study found that NITD609  
acted in a dose-dependent manner against the sexual gametocytes which are responsible for 
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transmission of the parasite [13] (Figures 7 & 8).  Most existing antimalarial drugs do not effect 
gametocytes therefore patients treated with these drugs can still transmit malaria.  NITD609 
was more effective in clearing gametocytes than lumefantrine, primaquine and artemether.  In 
this in vitro study the efficacy of NITD609 in clearing gametocytes could not be compared to 
that of primaquine which is used in human patients to prevent transmission in vivo as it does 
not have antimalarial activity in vitro. The lack of in vitro activity of primaquine was expected 
as it is a prodrug and it is necessary for it to be metabolised to induce its gametocytocidal 
properties.   NITD609 also decreased the oocyte count when added to the blood meal of 
mosquitos in a standard membrane feeding assay (SMFA) [13].   
These results showed that NITD609 not only acted on the asexual blood stages of the parasite 
but also on the sexual stages that are involved in transmission of malaria however higher 
concentrations were required. 
 
Figure 7.  Effect of antimalarial drugs on early gametocytes in vitro. Copied from [13]. 
 
 
Figure 8. Effect of antimalarial drugs on late gametocytes in vitro.  Copied from [13]. 
 
NITD609 did not prevent infection of P. berghei mice when given prophylactically before 
administration of a sporozoite injection [14].  This indicated that NITD609 was ineffective 
against the liver stages of Plasmodium.   
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Spiroindolones target PfATP4 
Using an incorporation assay with radiolabelled methionine and cysteine it was demonstrated 
that NITD609 blocked protein synthesis in P. falciparum within 1 hour [8,10] (Figure 9).  This 
effect was similar to that of the known protein translator inhibitors anisomycin and 
cycloheximide.  The effect of NITD609 was in contrast to the effect of artemisinin and 
mefloquine suggesting a different mechanism of action.  
 
Figure 9. Effect of NITD609 on protein synthesis in P. falciparum. Incorporation of 
radiolabelled methionine and cysteine after 1 hour of exposure was monitored to evaluated 
rate of parasite protein synthesis.  A: wild-type clones; B: NITD609-R drug-resistant clones.  
Copied from [10]. 
 
In vitro genetic methods were used to determine the likely target of NITD609 [10,15].  Malaria 
parasites were grown in the presence of a test compound until resistant strains developed.  
For NITD609 it took 3-4 months of in vitro selection to increase the IC50 7 to 10-fold [10,15] 
indicating that NITD609 does not readily select for high-level resistance in vitro.  Genomic 
analysis was used to compare the parent and resistant lines which enabled identification of 
the genes involved with the resistance.  Most of the differences in the NITD609-resistant line 
were found in the gene for the P-type cation-transporter ATPase4 (PfATP4).  This was 
supported by the reverse genetic approach of creating transgenic parasites with mutations on 
the PfATP4 and showing that these were resistant to the spiroindolones NITD609 and 
NITD678 but not artemisinin and mefloquine (Figure 10). 
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Figure 10.  NITD609 (A) and NITD678 (B) are less effective against parasites with pfatp4 
mutations.  Artemisinin (C) and  mefloquine (D) did were still effective against parasites with 
pfatp4 mutations.  Dd2attB: strain of parasite; PbEF1α: P. beghei promoter; PfCam: p. 
falciparum calmodulin promoter; wt: wildtype; D1247Y: resistant clone; P990R: resistant 
clone.  * P<0.0001 compared to DD2aatB strain.  Copied from [10]. 
 
The role of membrane transport proteins in the malaria parasite 
A malaria parasite that has infected a human erythrocyte needs to acquire key nutrients from 
the extracellular environment and export metabolites to support its high level of metabolic and 
biosynthetic activity whilst maintaining its own cytosolic composition.  The normal rate of 
uptake across the erythrocyte plasma membrane of some of these nutrients does not meet 
the requirements of the parasite and it may also be in competition with the host cell for these 
nutrients [16]. 
Human blood plasma is a high-[Na+]/low-[K+] environment and uninfected human erythrocytes 
are a low-[Na+]/high-[K+] environment [17].  Around 12-14 hours after entering a human 
erythrocyte P. falciparum creates new permeability pathways in the plasma membrane of the 
host erythrocyte increasing its permeability.  This enables the uptake of nutrients into the 
infected cell however also allows the flow of Na+ and K+ across their respective concentration 
gradients so they reach levels close to those in the extra-erythrocytic plasma [17].  Even 
though this causes increased [Na+] in its extracellular environment the parasite is able to 
maintain a low cytosolic [Na+] [17,18].   
Some protozoa and lower plants expel Na+ via an exitus natrus (ENA) P-type Na+-ATPase 
which is closely related to the sarcoplasmic/endoplasmic reticulum Ca2+-ATPases (SERCA) 
and plasma membrane Ca2+-ATPases (PMCA) [17].  It was known that the P. falciparum 
genome codes for 13 P-type ATPases, two of which are known to be Ca2+-ATPases but none 
had been identified as Na+-ATPase.   
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PfATP4 is a P-type Na+-ATPase 
PfATP4 belongs to a subclass (Type 4) of P-type ATPases that are unique to apicomplexan 
organisms [19].  Its absence in mammals makes it a good drug target.  Until recently it PfATP4 
was believed to be a P-type Ca2+-ATPase due to its similarity with the Ca2+-ATPases of the 
endoplasmic reticulum [19,20] however recent studies by indicated it is a P-type Na+-ATPase 
[17,21] (discussed in more detail later in this section). 
PfTP4 is a 190kDa protein found in the parasite plasma membrane [22].  Genetic sequencing 
showed it contained the features common to P-type ATPases including sequence motifs of a 
highly conserved phosphorylation site and nucleotide-binding site [19].  Modelling techniques 
indicated ten transmembrane helices and that mutations associated with spiroindolone 
resistance were localised in these transmembrane helices (Figure 11).  PfATP4 has an 
extended hydrophilic N-terminal region and lacks the long hydrophilic C-terminal seen in 
plasma-membrane-type ATPases.  The extended M7/M8 extracellular loop which is has a high 
proportion of acidic residues is predicted to be involved in ion transport [19]. 
 
Figure 11. Model of predicted structure of PfATP4.  Residues associated with mutations 
causing resistance are shown in red for NITD609-R and green for NITD678-R.   These 
mutations are located in the transmembrane helices.  Copied from [10] 
 
Spillman et al investigated the effect of a variety of ionophores and ion transport inhibitors on 
Na+ regulation in P. falciparum [17].  The known P-type ATPase inhibitor sodium 
orthovanadate impaired Na+ regulation as did the known ENA Na+-ATPase inhibitor 
furosemide suggesting the involvement of ENA P-type Na+-ATPase in maintaining the low 
cytosolic [Na+] despite the high extracellular levels.  Ouabain which inhibits all known  Na+/K+-
ATPases at the concentrations used had no significant effect on [Na+]I indicating that Na+/K+-
ATPases were not involved.  When the parasites were suspended in a glucose-free 
extracellular environment which causes depletion of ATP, there was an increase in [Na+]i 
which also supports the involvement of an ATPase in maintaining the low [Na+]i.  Analysis of 
the amino acid sequence showed that PfATP4 share an amino acid sequence that is known 
to be highly conserved in ENA Na+-ATPases and important for Na+ transport.  This sequence 
is not present in SERCA, PMCA or Na+/K+-ATPases.   
It is proposed that PfATP4 acts as an ENA Na+-ATPase and actively pumps Na+ out of the 
intra-erythrocytic parasite and that the efflux of Na+ is associated with an influx of H+ into the 
parasite (Figure 12) [17].  A further study demonstrated that the acid load caused by the influx 
of H+ is likely to be countered by the extrusion of H+ by a V-type H+-ATPase [21]. 
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Figure 12. Proposed mechanism of action of spiroindolones targeting PfATP4 in the 
plasma membrane of P. falciparum  [17].  Inhibition of PfATP4 by spiroindolones leads to a 
rise in intracellular Na+ and increase in intracellular pH. 
 
Spiroindolones inhibit PfATP4 
 
Spironindonlone IC50 inhibition of parasite 
proliferation (nM) 
IC50 disruption of Na+ regulation 
(nM) 
● NIDT246 0.12 ± 0.02 2.1 ± 0.8 
▿ NITD139 4.0 ± 5.8 16.6 ± 5.7 
■ NITD247 41.6 ± 5.8 407 ± 117 
◇ NITD138 2300 ±200 820000 ± 1700 
Figure 13.  The effect of four spiroindolones on the rate of influx of Na+. The order of 
potency for parasite proliferation inhibition corresponds with the order for Na+ disruption.  
Copied from [17]. 
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Four different spiroindolones were shown to cause an increase in [Na+] in a dose-dependent 
manner and the order of potency in increasing [Na+] corresponded their ranking inhibiting 
parasite proliferation [17] (Figure 13).  Spiroindolone NITD246 was shown to reduce 
membrane-associated ATPase activity in membrane preparations from infected erythrocytes 
suspended in a high concentration of Na+.  It was also shown that PfATP4 mutations 
corresponding with spiroindolone resistance reduced sensitivity to Na+ disruption and ATPase 
activity by spiroindolones.  These results supported the hypothesis that spiroindolones inhibit 
PfATP4 preventing sodium ions being pumped out of the parasite and leading to a fatal 
disruption of parasite sodium homeostasis (Figure 12).   
 
Determination of three dimensional structure required 
The three-dimensional structure of PfATP4 has been predicted using modelling techniques 
however it has not been determined by X-ray crystallography.  The structure of PfATP4 and 
its binding with ligands, including the spiroindolones and other drugs that target it should be 
ascertained.  Understanding the active sites of PfATP4 and the binding interactions that occur 
will allow more effective drugs to be created. 
 
Pharmacokinetics 
An important factor in a successful antimalarial treatment is ensuring patient compliance which 
can be improved by reducing the pill burden and treatment duration.  Existing antimalarial 
drugs have to be taken from one- to four-times daily for up to seven days [23] which is often 
difficult to achieve in areas where there is a lack of medical supervision. 
The pharmacokinetic properties observed when NITD609 was administered to mice and rats 
indicated that a once-daily dosing regimen might be appropriate (Table 3).  It had excellent 
oral bioavailability, a good half-life, moderate volume of distribution and low systemic 
clearance. 
 
 
 
Table 3.  Pharmacokinetic data for NITD609 in female CD-1 mice and Wistar rats.  i.v. = 
intravenous; p.o. = oral; Cmax = maximum drug serum concentration; Tmax = Time at which Cmax 
observed; AUC = area under curve; F = oral bioavailability; Vss = volume of distribution; CL – 
clearance; T1/2 Elim = Half-life. Copied from [10]. 
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Safety and selectivity of NITD609 in vitro 
The safety of a new antimalarial drugs is essential, particularly due to the vulnerability of the 
patient population, which includes many young children, pregnant women and those with 
comorbidities, living in areas that often have limited medical resources.  The malaria parasite 
within the human body is the intended target for NITD609 therefore it is important that it is 
not cytotoxic to human cells at the concentrations required for parasite cytotoxicity.  
NITD609 showed no significant cytotoxicity against a panel of in vitro mammalian cell lines 
[10].  For each of the cell lines tested the concentration of NITD609 that lead to 50% cell 
death (CC50) was at least 10μM.  Since the IC50 was < 1nM the selectivity index (CC50/IC50) > 
10,000.  Some antimalarial drugs can be cardiotoxic as they inhibit hERG channels however 
NITD609 showed low binding affinity to hERG as well as other human ion channels, G-
protein coupled receptors and enzymes.  When administered to rats for 14 days at 10-20 
times the calculated effective dose required to reduce parasitaemia by 99% (ED99) there 
were no adverse events observed. 
 
Clinical trials 
NITD609 (which is now known as KAE609 or cipargamin) underwent a phase 2 clinical trial in 
3 locations in Thailand to assess its antimalarial efficacy, safety and adverse events 
(ClinicalTrials.gov number NCT01524341) [24].  KAE609 was administered to adults with 
uncomplicated P. vivax or P. falciparum malaria at 30mg per day for 3 days.  This was a small 
study with only 21 patients however the results were very encouraging.  KAE609 cleared the 
parasites rapidly from the blood of the patients with median complete parasite clearance time 
of 12 hours.  The median parasite half-life clearance was 0.95 hours for P. vivax and 0.90 
hours for P. falciparum which is excellent when considered compared to artensunate for which 
less than 1% of patients infected with P. falciparum have half-life clearance of under 1 hour. 
The safety, tolerability and pharmacokinetics of KAE609 in healthy male adult patients after 
single and multiple oral dosing was assessed in a randomised, double-blind, placebo-
controlled study [25].  KAE609 was generally well tolerated however some mild to moderate 
adverse events were recorded which were mostly gastrointestinal and genitourinary and 
increased with rising doses. 
Two further clinical trials are scheduled [26].  One to find the minimum inhibitory concentration 
for a single dose of KAE609 to reduce parasitaemia to zero in adult male patients with P. 
falciparum monoinfection (ClinicalTrials.gov Identifier: NCT01836458), this will help to identify 
the optimal dose of KAE609.  The other to assess the efficacy and safety of KAE609 in adults 
with acute malaria mono-infection (ClinicalTrials.gov Identifier: NCT01860989). 
 
PfATP4 pathway targeted by diverse structures 
In a recent in vitro study 28 out of 400 (7%) compounds in the ‘Malaria Box’ affected Na+ and 
pH regulation in a manner consistent with PfATP4 inhibition [27].  Six of these, which had 
chemically diverse structures, were analysed further and were all found to have reduced 
efficacy against spiroindolone-resistant parasites with pfatp4 mutations indicating that they all 
interact with PfATP4.   These results suggest that PfATP4 is important for parasite survival, 
can be inhibited by a variety of compounds and is readily accesses by compounds in the 
extracellular medium.  Researchers at GlaxoSmithKline have identified at least four further 
scaffolds unrelated to NITD609 that may act via the same PfATP4 pathway [28].  These results 
indicate that PfATP4 may be an important target in the fight against malaria and certainly 
warrants further research to understand its action, molecular structure and binding sites. 
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Repurposing of NITD609 for use against other apicomplexan parasites 
As well as its activity against Plasmodium, NITD609 is also active against the related 
apicomplexan parasite Toxoplasma gondii which causes toxoplasmosis [29].  T. gondii 
ATPase4 (TgATP4), which corresponds to PfATP4, was identified as the likely target.  
Modelling techniques showed that PfATP4 and TgATP4 share a large degree of sequence 
identity particularly around the transmembrane region of the ATPase4 structure where the 
spiroindolone binding site is proposed to be and the residues involved in drug resistance 
(Figure 14). 
 
Figure 14. Modelled structure of TgATP4.  Green indicates residues that differ significantly 
between T. gondii, P. falciparum and P. vivax.  Magenta spheres indicates residues altered in 
spiroindolones resistance.  Copied from [29] 
 
 
Future perspective  
NITD609 is currently in Phase II clinical trials and is the first antimalarial drug with a novel 
action to reach this stage since atovaquone/proguanil in 1996 [8].  To reduce the risk of 
resistance developing antimalarial drugs should always be administered in combination 
therefore if it is successful in clinical trials a suitable partner drug will need to be identified 
which could delay its introduction into clinical use. 
PfATP4 is emerging as an important target in the fight against malaria and further research is 
needed to understand its structure, function and how drugs may target it in the fight against 
malaria.  The three-dimensional, crystal structure of the PfATP4 protein should be determined 
as well as its binding interactions with the spiroindolones and some of the diverse compounds 
from the Malaria Box.  With this knowledge a rational approach can be utilised to create further 
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drugs for the treatment of malaria and possibly other apicomplexan parasites such as 
Toxoplasma gondii. 
 
Executive Summary:  
 Resistance of Plasmodium to artemisinin emphasises the need for new antimalarial 
drugs with a novel mode of action. 
 Spiroindolones were discovered to have antimalarial activity using whole-cell 
screening methods however their target and mode of action were unknown. 
 It was determined that the 1R,3S configuration was required for activity against 
Plasmodium. 
 Optimisation of the spiroindolone using SAR analysis lead improved both potency and 
pharmacokinetics and led to drug candidate NIT609. 
 Spiroindolones inhibit PfATP4 of the Plasmodium parasite resulting in a fatal increase 
in sodium ions in the parasite. 
 PfATP4 is a P-type Na+-ATPase located in the parasite plasma membrane that pumps 
sodium ions out of the parasite. 
 The spiroindolones have a distinct mechanism of action from the existing antimalarial 
drugs.  
 In vitro spiroindolones do not readily select for resistance and do not show cross-
resistance to existing antimalarial drugs. 
 Pharmacokinetic studies indicate NITD609 may be compatible with once-daily oral 
dosing. 
 NITD609 is currently in Phase 2 clinical trials where so far it has shown encouraging 
results. 
 The crystal structure of PfATP4 and its binding interactions with the spiroindolones or 
other drugs has not been determined. 
 Other compounds in the Malaria Box, with diverse molecular structures, also appear 
to target PfATP4.  This suggest that PfATP4 is an important target that should be 
investigated further. 
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